Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Opsoclonus-myoclonus syndrome

Orpha number ORPHA1183
Synonym(s) Ataxo-opso-myoclonus syndrome
Dancing eye syndrome
Kinsbourne syndrome
OMA syndrome
OMS
Opsoclonus-myoclonus-ataxia syndrome
POMA syndrome
Paraneoplastic opsoclonus-myoclonus
Paraneoplastic opsoclonus-myoclonus-ataxia syndrome
Prevalence Unknown
Inheritance Not applicable
Age of onset Childhood
ICD-10 -
ICD-O -
OMIM -
UMLS
  • C0393626
  • C1096154
MeSH
  • D053578
MedDRA
  • 10053854

Summary

Opsoclonus myoclonus syndrome (OMS) is a rare pediatric brain inflammatory disease of paraneoplastic, parainfectious or idiopathic origin, characterized by opsoclonus, myoclonus, ataxia and behavioural and sleep disorders.

The annual incidence is estimated at around 1/5,000,000.

OMS typically occurs between 1 and 3 years of age, although it can occur earlier or later in childhood. It is characterized by opsoclonus (rapid, multi-directional, conjugate eye movements), myoclonic jerks, ataxia, irritability and sleep disturbance. The clinical course may be monophasic or chronic relapsing. OMS is associated in approximately 50% of pediatric cases with a neuroblastoma (see this term); this tumour is usually (but not invariably) of low grade with a good oncological outcome. A similar adult-onset condition also occurs but it is associated with different types of cancer, most commonly small-cell lung cancer (see this term) and adenocarcinoma of the breast.

OMS may have a paraneoplastic, parainfectious or idiopathic origin. In the majority of pediatric paraneoplastic cases, a neuroblastoma is found. Infections triggering OMS include a variety of viral and bacterial agents including streptococci, mycoplasma and varicella zoster. The exact pathomechanism is unknown but an autoimmune-mediated brainstem and/or cerebellar dysfunction has been suggested; the opsoclonus may reflect disinhibition of the fastigial nucleus of the cerebellum or disordered interaction between the omnipause and burst neurons but the cognitive and behavioral elements of the condition - as well as recent imaging studies - suggest a wider neurological process.

The diagnosis is clinical, based on the presence of 3 out of the 4 following criteria: 1) neuroblastoma, 2) opsoclonus, 3) a movement disorder with myoclonus and/or ataxia, and 4) behavioural and/or sleep disturbance. Brain MRI in the acute presentation is normal. Neuroblastoma is detected by detailed MRI with particular focus on the whole length para-spinal regions, the carotids, the mediastinum, the adrenals, the abdomen and pelvis. Functional tests, including urinary vanillylmandelic and homovanillic acid and metaiodobenzylguanidine scan, should be performed but may produce a false negative result because neuroblastomas in OMS are usually low grade and therefore not metabolically active. Serological tests may allow identification of a para-infectious etiology. No consistent neural antibody has yet been identified in pediatric OMS, in contrast to adult OMS in which Hu anti-neuronal nuclear antibodies (anti-Hu) have been found.

Differential diagnosis includes acute inflammatory cerebellar ataxia that is differentiated from OMS by the type of eye movement (nystagmus), the absence of irritability, and the usually rapid recovery without treatment.

Treatment usually includes resection of the neuroblastoma if present; occasionally, higher grade neuroblastoma may require chemotherapy. Treatment also includes immunomodulation. Treatment regimens have not been standardized but may include corticosteroids, adrenocorticotropin hormone,cyclophosphamide, intravenous immunoglobulin, and/or rituximab. A clinical trial using steroids and cyclophosphamide combined or not with immunoglobulins has been completed and data is being currently analyzed in the USA, while another one based on a stepwise approach (monthly dexamethasone pulses, followed, in case of insufficient response, by administration of cyclophosphamide, and then rituximab) is ongoing in Europe.

Outcome is variable. Some children have a monophasic illness, respond well to steroids and have little or no sequelae. Others may have treatment-resistance, a chronic relapsing course and motor, cognitive and/or behavioral sequelae. Opsoclonus usually remits. The presence or absence of neuroblastoma does not seem to affect outcome.

Expert reviewer(s)

  • Dr Mark GORMAN
  • Dr Michael PIKE
  • Pr Marc TARDIEU

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.